Search hospitals

>

Rhode Island

>

Providence

Rhode Island Hospital

Claim this profile

Providence, Rhode Island 02903

Global Leader in Cancer

Global Leader in Breast Cancer

Conducts research for Lung Cancer

Conducts research for Leukemia

Conducts research for Solid Tumors

856 reported clinical trials

62 medical researchers

Photo of Rhode Island Hospital in ProvidencePhoto of Rhode Island Hospital in ProvidencePhoto of Rhode Island Hospital in Providence

Summary

Rhode Island Hospital is a medical facility located in Providence, Rhode Island. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Leukemia, Solid Tumors and other specialties. Rhode Island Hospital is involved with conducting 856 clinical trials across 1,090 conditions. There are 62 research doctors associated with this hospital, such as Jennifer J. Welch, Bradley DeNardo, Benedito Carneiro, and Adam J. Olszewski.

Area of expertise

1

Cancer

Global Leader

Rhode Island Hospital has run 61 trials for Cancer. Some of their research focus areas include:

Stage IV
Stage I
Stage II
2

Breast Cancer

Global Leader

Rhode Island Hospital has run 54 trials for Breast Cancer. Some of their research focus areas include:

HER2 positive
HER2 negative
ER positive

Top PIs

Clinical Trials running at Rhode Island Hospital

Breast Cancer

Lung Cancer

Breast cancer

Testicular cancer

Neuroblastoma

Insomnia

Brain Tumor

Non-Small Cell Lung Cancer

Cancer

Leukemia

Image of trial facility.

Imlunestrant

for Early Breast Cancer

This trial is testing a new medication called imlunestrant to see if it works better than standard hormone treatments for certain breast cancer patients. The study focuses on patients with early-stage breast cancer that is estrogen receptor positive and HER2 negative, who have already been on hormone therapy for a period of time and are at high risk of their cancer returning. Imlunestrant works by blocking estrogen from helping cancer cells grow.

Recruiting

2 awards

Phase 3

6 criteria

Image of trial facility.

Elacestrant

for Breast Cancer

The primary goal of this study is to evaluate the effectiveness of elacestrant versus standard endocrine therapy in participants with node-positive, Estrogen Receptor-positive (ER+), Human Epidermal Growth Factor-2 negative (HER2-) early breast cancer with high risk of recurrence.

Recruiting

2 awards

Phase 3

3 criteria

Image of trial facility.

HER2-Targeted Therapy

for Breast Cancer

This phase III trial compares 6 months of human epidermal growth factor receptor 2 (HER2)-targeted therapy to 12 months of HER2-targeted therapy for the treatment of HER2-positive (+) breast cancer in patients that had a pathologic complete response (pCR) after preoperative (neoadjuvant) chemotherapy with trastuzumab. Trastuzumab and pertuzumab are monoclonal antibodies and forms of targeted therapy that attach to a receptor protein called HER2. HER2 is found on some cancer cells. When trastuzumab or pertuzumab attach to HER2, the signals that tell the cells to grow are blocked and the tumor cell may be marked for destruction by the body's immune system. Giving 6 months of HER2-targeted therapy may work better than giving 12 months for the treatment of HER2+ breast cancer in patients that had a pCR after neoadjuvant chemotherapy with trastuzumab.

Recruiting

2 awards

Phase 3

5 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Rhode Island Hospital?

Where is Rhode Island Hospital located?

Who should I call to ask about financial aid or insurance network?

What insurance does Rhode Island Hospital accept?

What awards or recognition has Rhode Island Hospital received?